Safety and tolerability of lamotrigine: Results from 12 placebo-controlled clinical trials and clinical implications

Ho Jun Seo, Alberto Chiesa, Soo Jung Lee, Ashwin A. Patkar, Changsu Han, Prakash S. Masand, Alessandro Serretti, Chi Un Pae

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

The mechanism of action of lamotrigine depends on voltage-sensitive sodium channels by which the neuronal membrane is stabilized and the release of excitatory neurotransmitters, such as glutamate and aspartate, is inhibited. Lamotrigine is indicated for maintenance treatment of bipolar I disorder to delay the time to the occurrence of mood episodes for those treated for acute mood episodes with standard therapy. There are significant gaps between clinical practices and research settings; data from controlled clinical trials of lamotrigine provide essential information about safety in bipolar populations because they result from large samples of patients with a specific disease and include comparisons with placebo or other comparators with randomized designs. In addition, lamotrigine's safety and tolerability data differ slightly in relation to disease entities, age ranges of the patients taking lamotrigine, and treatment conditions. For example, the incidence of serious rashes, including Stevens-Johnson syndrome, is approximately 0.8% (8/1000) in pediatric patients (2-16 years of age) receiving lamotrigine as adjunctive therapy for epilepsy and 0.3% (3/1000) in adults on adjunctive therapy for epilepsy. In clinical trials of bipolar and other mood disorders, the rate of serious rash was 0.08% (0.8/1000) in adult patients receiving lamotrigine as initial monotherapy and 0.13% (1.3/1000) in adult patients receiving lamotrigine as adjunctive therapy.Hence, in this study, we focus on the data regarding the safety and tolerability of lamotrigine in the treatment of bipolar disorder gathered from 12 placebo-controlled trials, regardless of publication status, that were sponsored by GlaxoSmithKline. We also inform clinicians of practical issues in safety and tolerability in the use of lamotrigine in the treatment of bipolar disorders.

Original languageEnglish
Pages (from-to)39-47
Number of pages9
JournalClinical Neuropharmacology
Volume34
Issue number1
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

Controlled Clinical Trials
Placebos
Safety
Bipolar Disorder
Therapeutics
Exanthema
Epilepsy
lamotrigine
Stevens-Johnson Syndrome
Sodium Channels
Mood Disorders
Aspartic Acid
Neurotransmitter Agents
Publications
Glutamic Acid
Clinical Trials
Pediatrics
Membranes
Incidence

Keywords

  • lamotrigine
  • safety
  • tolerability

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Safety and tolerability of lamotrigine : Results from 12 placebo-controlled clinical trials and clinical implications. / Seo, Ho Jun; Chiesa, Alberto; Lee, Soo Jung; Patkar, Ashwin A.; Han, Changsu; Masand, Prakash S.; Serretti, Alessandro; Pae, Chi Un.

In: Clinical Neuropharmacology, Vol. 34, No. 1, 01.01.2011, p. 39-47.

Research output: Contribution to journalReview article

Seo, Ho Jun ; Chiesa, Alberto ; Lee, Soo Jung ; Patkar, Ashwin A. ; Han, Changsu ; Masand, Prakash S. ; Serretti, Alessandro ; Pae, Chi Un. / Safety and tolerability of lamotrigine : Results from 12 placebo-controlled clinical trials and clinical implications. In: Clinical Neuropharmacology. 2011 ; Vol. 34, No. 1. pp. 39-47.
@article{cf340a30ee044af3a8fe70c9393bba04,
title = "Safety and tolerability of lamotrigine: Results from 12 placebo-controlled clinical trials and clinical implications",
abstract = "The mechanism of action of lamotrigine depends on voltage-sensitive sodium channels by which the neuronal membrane is stabilized and the release of excitatory neurotransmitters, such as glutamate and aspartate, is inhibited. Lamotrigine is indicated for maintenance treatment of bipolar I disorder to delay the time to the occurrence of mood episodes for those treated for acute mood episodes with standard therapy. There are significant gaps between clinical practices and research settings; data from controlled clinical trials of lamotrigine provide essential information about safety in bipolar populations because they result from large samples of patients with a specific disease and include comparisons with placebo or other comparators with randomized designs. In addition, lamotrigine's safety and tolerability data differ slightly in relation to disease entities, age ranges of the patients taking lamotrigine, and treatment conditions. For example, the incidence of serious rashes, including Stevens-Johnson syndrome, is approximately 0.8{\%} (8/1000) in pediatric patients (2-16 years of age) receiving lamotrigine as adjunctive therapy for epilepsy and 0.3{\%} (3/1000) in adults on adjunctive therapy for epilepsy. In clinical trials of bipolar and other mood disorders, the rate of serious rash was 0.08{\%} (0.8/1000) in adult patients receiving lamotrigine as initial monotherapy and 0.13{\%} (1.3/1000) in adult patients receiving lamotrigine as adjunctive therapy.Hence, in this study, we focus on the data regarding the safety and tolerability of lamotrigine in the treatment of bipolar disorder gathered from 12 placebo-controlled trials, regardless of publication status, that were sponsored by GlaxoSmithKline. We also inform clinicians of practical issues in safety and tolerability in the use of lamotrigine in the treatment of bipolar disorders.",
keywords = "lamotrigine, safety, tolerability",
author = "Seo, {Ho Jun} and Alberto Chiesa and Lee, {Soo Jung} and Patkar, {Ashwin A.} and Changsu Han and Masand, {Prakash S.} and Alessandro Serretti and Pae, {Chi Un}",
year = "2011",
month = "1",
day = "1",
doi = "10.1097/WNF.0b013e3182055c07",
language = "English",
volume = "34",
pages = "39--47",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Safety and tolerability of lamotrigine

T2 - Results from 12 placebo-controlled clinical trials and clinical implications

AU - Seo, Ho Jun

AU - Chiesa, Alberto

AU - Lee, Soo Jung

AU - Patkar, Ashwin A.

AU - Han, Changsu

AU - Masand, Prakash S.

AU - Serretti, Alessandro

AU - Pae, Chi Un

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The mechanism of action of lamotrigine depends on voltage-sensitive sodium channels by which the neuronal membrane is stabilized and the release of excitatory neurotransmitters, such as glutamate and aspartate, is inhibited. Lamotrigine is indicated for maintenance treatment of bipolar I disorder to delay the time to the occurrence of mood episodes for those treated for acute mood episodes with standard therapy. There are significant gaps between clinical practices and research settings; data from controlled clinical trials of lamotrigine provide essential information about safety in bipolar populations because they result from large samples of patients with a specific disease and include comparisons with placebo or other comparators with randomized designs. In addition, lamotrigine's safety and tolerability data differ slightly in relation to disease entities, age ranges of the patients taking lamotrigine, and treatment conditions. For example, the incidence of serious rashes, including Stevens-Johnson syndrome, is approximately 0.8% (8/1000) in pediatric patients (2-16 years of age) receiving lamotrigine as adjunctive therapy for epilepsy and 0.3% (3/1000) in adults on adjunctive therapy for epilepsy. In clinical trials of bipolar and other mood disorders, the rate of serious rash was 0.08% (0.8/1000) in adult patients receiving lamotrigine as initial monotherapy and 0.13% (1.3/1000) in adult patients receiving lamotrigine as adjunctive therapy.Hence, in this study, we focus on the data regarding the safety and tolerability of lamotrigine in the treatment of bipolar disorder gathered from 12 placebo-controlled trials, regardless of publication status, that were sponsored by GlaxoSmithKline. We also inform clinicians of practical issues in safety and tolerability in the use of lamotrigine in the treatment of bipolar disorders.

AB - The mechanism of action of lamotrigine depends on voltage-sensitive sodium channels by which the neuronal membrane is stabilized and the release of excitatory neurotransmitters, such as glutamate and aspartate, is inhibited. Lamotrigine is indicated for maintenance treatment of bipolar I disorder to delay the time to the occurrence of mood episodes for those treated for acute mood episodes with standard therapy. There are significant gaps between clinical practices and research settings; data from controlled clinical trials of lamotrigine provide essential information about safety in bipolar populations because they result from large samples of patients with a specific disease and include comparisons with placebo or other comparators with randomized designs. In addition, lamotrigine's safety and tolerability data differ slightly in relation to disease entities, age ranges of the patients taking lamotrigine, and treatment conditions. For example, the incidence of serious rashes, including Stevens-Johnson syndrome, is approximately 0.8% (8/1000) in pediatric patients (2-16 years of age) receiving lamotrigine as adjunctive therapy for epilepsy and 0.3% (3/1000) in adults on adjunctive therapy for epilepsy. In clinical trials of bipolar and other mood disorders, the rate of serious rash was 0.08% (0.8/1000) in adult patients receiving lamotrigine as initial monotherapy and 0.13% (1.3/1000) in adult patients receiving lamotrigine as adjunctive therapy.Hence, in this study, we focus on the data regarding the safety and tolerability of lamotrigine in the treatment of bipolar disorder gathered from 12 placebo-controlled trials, regardless of publication status, that were sponsored by GlaxoSmithKline. We also inform clinicians of practical issues in safety and tolerability in the use of lamotrigine in the treatment of bipolar disorders.

KW - lamotrigine

KW - safety

KW - tolerability

UR - http://www.scopus.com/inward/record.url?scp=79551584480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551584480&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e3182055c07

DO - 10.1097/WNF.0b013e3182055c07

M3 - Review article

C2 - 21242744

AN - SCOPUS:79551584480

VL - 34

SP - 39

EP - 47

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 1

ER -